IL-33 is negatively associated with the BMI and confers a protective lipid/metabolic profile in non-diabetic but not diabetic subjects

Amal Hasan, Fahad Al-Ghimlas, Samia Warsame, Asma Al-Hubail, Rasheed Ahmad, Abdullah Bennakhi, Monira Al-Arouj, Kazem Behbehani, Mohammed Dehbi, Said Dermime

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Objective: Recent studies have demonstrated a protective role for IL-33 against obesity-associated inflammation, atherosclerosis and metabolic abnormalities. IL-33 promotes the production of T helper type 2 (Th2) cytokines, polarizes macrophages towards a protective alternatively activated phenotype, reduces lipid storage and decreases the expression of genes associated with lipid metabolism and adipogenesis. Our objective was to determine the level of serum IL-33 in non-diabetic and diabetic subjects, and to correlate these levels with clinical (BMI and body weight) and metabolic (serum lipids and HbA1c) parameters. Methods: The level of IL-33 was measured in the serum of lean, overweight and obese non-diabetic and diabetic subjects, and then correlated with clinical and metabolic parameters. Results: Non-lean subjects had significantly (P = 0.01) lower levels of IL-33 compared to lean controls. IL-33 was negatively correlated with the BMI and body weight in lean and overweight, but not obese (non-diabetic and diabetic), subjects. IL-33 is associated with protective lipid profiles, and is negatively correlated with HbA1c, in non-diabetic (lean, overweight and obese) but not diabetic subjects. Conclusions: Our data support previous findings showing a protective role for IL-33 against adiposity and atherosclerosis, and further suggest that reduced levels of IL-33 may put certain individuals at increased risk of developing atherosclerosis and insulin resistance. Therefore, IL-33 may serve as a novel marker to predict those who may be at increased risk of developing atherosclerosis.

Original languageEnglish
Article number19
JournalBMC Immunology
Volume15
Issue number1
DOIs
Publication statusPublished - 10 May 2014
Externally publishedYes

Fingerprint

Metabolome
Lipids
Atherosclerosis
Serum
Body Weight
Interleukin-33
Adipogenesis
Adiposity
Lipid Metabolism
Insulin Resistance
Obesity
Macrophages
Cytokines
Inflammation
Phenotype
Gene Expression

Keywords

  • Atherosclerosis
  • BMI
  • HDL-C
  • Interleukin-33
  • LDL-C
  • TGL

ASJC Scopus subject areas

  • Immunology

Cite this

IL-33 is negatively associated with the BMI and confers a protective lipid/metabolic profile in non-diabetic but not diabetic subjects. / Hasan, Amal; Al-Ghimlas, Fahad; Warsame, Samia; Al-Hubail, Asma; Ahmad, Rasheed; Bennakhi, Abdullah; Al-Arouj, Monira; Behbehani, Kazem; Dehbi, Mohammed; Dermime, Said.

In: BMC Immunology, Vol. 15, No. 1, 19, 10.05.2014.

Research output: Contribution to journalArticle

Hasan, A, Al-Ghimlas, F, Warsame, S, Al-Hubail, A, Ahmad, R, Bennakhi, A, Al-Arouj, M, Behbehani, K, Dehbi, M & Dermime, S 2014, 'IL-33 is negatively associated with the BMI and confers a protective lipid/metabolic profile in non-diabetic but not diabetic subjects', BMC Immunology, vol. 15, no. 1, 19. https://doi.org/10.1186/1471-2172-15-19
Hasan, Amal ; Al-Ghimlas, Fahad ; Warsame, Samia ; Al-Hubail, Asma ; Ahmad, Rasheed ; Bennakhi, Abdullah ; Al-Arouj, Monira ; Behbehani, Kazem ; Dehbi, Mohammed ; Dermime, Said. / IL-33 is negatively associated with the BMI and confers a protective lipid/metabolic profile in non-diabetic but not diabetic subjects. In: BMC Immunology. 2014 ; Vol. 15, No. 1.
@article{1a62af8f5b124344a3d392d4bfd73993,
title = "IL-33 is negatively associated with the BMI and confers a protective lipid/metabolic profile in non-diabetic but not diabetic subjects",
abstract = "Objective: Recent studies have demonstrated a protective role for IL-33 against obesity-associated inflammation, atherosclerosis and metabolic abnormalities. IL-33 promotes the production of T helper type 2 (Th2) cytokines, polarizes macrophages towards a protective alternatively activated phenotype, reduces lipid storage and decreases the expression of genes associated with lipid metabolism and adipogenesis. Our objective was to determine the level of serum IL-33 in non-diabetic and diabetic subjects, and to correlate these levels with clinical (BMI and body weight) and metabolic (serum lipids and HbA1c) parameters. Methods: The level of IL-33 was measured in the serum of lean, overweight and obese non-diabetic and diabetic subjects, and then correlated with clinical and metabolic parameters. Results: Non-lean subjects had significantly (P = 0.01) lower levels of IL-33 compared to lean controls. IL-33 was negatively correlated with the BMI and body weight in lean and overweight, but not obese (non-diabetic and diabetic), subjects. IL-33 is associated with protective lipid profiles, and is negatively correlated with HbA1c, in non-diabetic (lean, overweight and obese) but not diabetic subjects. Conclusions: Our data support previous findings showing a protective role for IL-33 against adiposity and atherosclerosis, and further suggest that reduced levels of IL-33 may put certain individuals at increased risk of developing atherosclerosis and insulin resistance. Therefore, IL-33 may serve as a novel marker to predict those who may be at increased risk of developing atherosclerosis.",
keywords = "Atherosclerosis, BMI, HDL-C, Interleukin-33, LDL-C, TGL",
author = "Amal Hasan and Fahad Al-Ghimlas and Samia Warsame and Asma Al-Hubail and Rasheed Ahmad and Abdullah Bennakhi and Monira Al-Arouj and Kazem Behbehani and Mohammed Dehbi and Said Dermime",
year = "2014",
month = "5",
day = "10",
doi = "10.1186/1471-2172-15-19",
language = "English",
volume = "15",
journal = "BMC Immunology",
issn = "1471-2172",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - IL-33 is negatively associated with the BMI and confers a protective lipid/metabolic profile in non-diabetic but not diabetic subjects

AU - Hasan, Amal

AU - Al-Ghimlas, Fahad

AU - Warsame, Samia

AU - Al-Hubail, Asma

AU - Ahmad, Rasheed

AU - Bennakhi, Abdullah

AU - Al-Arouj, Monira

AU - Behbehani, Kazem

AU - Dehbi, Mohammed

AU - Dermime, Said

PY - 2014/5/10

Y1 - 2014/5/10

N2 - Objective: Recent studies have demonstrated a protective role for IL-33 against obesity-associated inflammation, atherosclerosis and metabolic abnormalities. IL-33 promotes the production of T helper type 2 (Th2) cytokines, polarizes macrophages towards a protective alternatively activated phenotype, reduces lipid storage and decreases the expression of genes associated with lipid metabolism and adipogenesis. Our objective was to determine the level of serum IL-33 in non-diabetic and diabetic subjects, and to correlate these levels with clinical (BMI and body weight) and metabolic (serum lipids and HbA1c) parameters. Methods: The level of IL-33 was measured in the serum of lean, overweight and obese non-diabetic and diabetic subjects, and then correlated with clinical and metabolic parameters. Results: Non-lean subjects had significantly (P = 0.01) lower levels of IL-33 compared to lean controls. IL-33 was negatively correlated with the BMI and body weight in lean and overweight, but not obese (non-diabetic and diabetic), subjects. IL-33 is associated with protective lipid profiles, and is negatively correlated with HbA1c, in non-diabetic (lean, overweight and obese) but not diabetic subjects. Conclusions: Our data support previous findings showing a protective role for IL-33 against adiposity and atherosclerosis, and further suggest that reduced levels of IL-33 may put certain individuals at increased risk of developing atherosclerosis and insulin resistance. Therefore, IL-33 may serve as a novel marker to predict those who may be at increased risk of developing atherosclerosis.

AB - Objective: Recent studies have demonstrated a protective role for IL-33 against obesity-associated inflammation, atherosclerosis and metabolic abnormalities. IL-33 promotes the production of T helper type 2 (Th2) cytokines, polarizes macrophages towards a protective alternatively activated phenotype, reduces lipid storage and decreases the expression of genes associated with lipid metabolism and adipogenesis. Our objective was to determine the level of serum IL-33 in non-diabetic and diabetic subjects, and to correlate these levels with clinical (BMI and body weight) and metabolic (serum lipids and HbA1c) parameters. Methods: The level of IL-33 was measured in the serum of lean, overweight and obese non-diabetic and diabetic subjects, and then correlated with clinical and metabolic parameters. Results: Non-lean subjects had significantly (P = 0.01) lower levels of IL-33 compared to lean controls. IL-33 was negatively correlated with the BMI and body weight in lean and overweight, but not obese (non-diabetic and diabetic), subjects. IL-33 is associated with protective lipid profiles, and is negatively correlated with HbA1c, in non-diabetic (lean, overweight and obese) but not diabetic subjects. Conclusions: Our data support previous findings showing a protective role for IL-33 against adiposity and atherosclerosis, and further suggest that reduced levels of IL-33 may put certain individuals at increased risk of developing atherosclerosis and insulin resistance. Therefore, IL-33 may serve as a novel marker to predict those who may be at increased risk of developing atherosclerosis.

KW - Atherosclerosis

KW - BMI

KW - HDL-C

KW - Interleukin-33

KW - LDL-C

KW - TGL

UR - http://www.scopus.com/inward/record.url?scp=84902254678&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902254678&partnerID=8YFLogxK

U2 - 10.1186/1471-2172-15-19

DO - 10.1186/1471-2172-15-19

M3 - Article

VL - 15

JO - BMC Immunology

JF - BMC Immunology

SN - 1471-2172

IS - 1

M1 - 19

ER -